Long term antiretroviral injection proves effective in trial
BMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j3577 (Published 24 July 2017) Cite this as: BMJ 2017;358:j3577- Sophie Cousins
- Paris
A long acting injection for HIV could transform antiretroviral therapy (ART) for patients who struggle to take a daily pill, a leading doctor has said, after the first study of a fully injectable antiretroviral regimen found it to be effective.
Research presented at the International AIDS Society’s Conference on HIV Science in Paris, France, showed that a four or eight week maintenance ART injection of cabotegravir plus rilpivirine had high rates of virologic response and was well tolerated through 96 weeks.
At the end of a two year trial of 286 people, 94% of patients who had received the eight week injection and 87% of those who had the four week injection had the virus under control, defined as …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.